Human chorionic gonadotrophin luteal support overcomes luteal phase inadequacy after gonadotrophin-releasing hormone agonist-induced ovulation in gonadotrophin-stimulated cycles.

Peñarrubia J, Balasch J, Fábregues F, Creus M, Casamitjana R, Ballescá JL, Puerto B, Vanrell JA

Human reproduction (Oxford, England)1 Dec 1998Cited by 23 (Europe PMC)

PMID9886506DOI10.1093/humrep/13.12.3315PepBankPUB-09886506

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

01HumanNon-randomized trialEfficacy outcome
In women undergoing ovarian stimulation, all leuprolide-triggered and HCG-triggered cycles were ovulatory, with mid-luteal progesterone >10 ng/ml.
In plain wordsIn women undergoing ovarian stimulation, all cycles were ovulatory after either leuprolide or HCG triggering.
Peptide
Leuprolide
Outcome
Not applicableOvulation
Study
n = 52
Comparator
HCG 10,000 IU for ovulation induction with the same HCG luteal support
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
0.5 mg single doseAs given in this study (human).
Measurements
Mid-luteal serum progesterone
> 10 ng/ml
all cycles, both groups
Source sentences
Summary
All cycles were ovulatory as shown by mid-luteal serum progesterone concentrations >10 ng/ml.
3 context sentences(design, population, supporting numbers)
Summary · context
The present report investigated the luteal phase in non-conceptual polyfollicular cycles in 26 patients (group 1) receiving a single dose of 0.5 mg leuprolide acetate to induce ovulation and in a control group of patients (n = 26) (group 2) who were given human chorionic gonadotrophin (HCG) (10,000…
Summary · context
All of them were normal ovulatory women undergoing gonadotrophin ovarian stimulation because of unexplained infertility or male factor.
Summary · context
In both groups of patients two doses of 2500 IU HCG i.m. were given 6 and 10 days after the ovulatory dose of HCG or GnRHa to support the luteal phase.
Report a problemFND-0988650601
02HumanNon-randomized trialEfficacy outcome
In women undergoing ovarian stimulation, mean progesterone was lower with leuprolide triggering than HCG triggering, without statistical significance.
In plain wordsIn women undergoing ovarian stimulation, progesterone was lower with leuprolide than HCG triggering, but the difference was not significant.
Peptide
Leuprolide
Outcome
DecreaseMean serum progesterone
Study
n = 52
Comparator
HCG 10,000 IU for ovulation induction with the same HCG luteal support
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
0.5 mg single doseAs given in this study (human).
Measurements
Progesterone difference
62%
HCG group higher than leuprolide group
Source sentences
Summary
Mean serum progesterone concentrations were 62% higher in group 2 than in group 1, but this difference was not statistically significant.
3 context sentences(design, population, supporting numbers)
Summary · context
The present report investigated the luteal phase in non-conceptual polyfollicular cycles in 26 patients (group 1) receiving a single dose of 0.5 mg leuprolide acetate to induce ovulation and in a control group of patients (n = 26) (group 2) who were given human chorionic gonadotrophin (HCG) (10,000…
Summary · context
All of them were normal ovulatory women undergoing gonadotrophin ovarian stimulation because of unexplained infertility or male factor.
Summary · context
In both groups of patients two doses of 2500 IU HCG i.m. were given 6 and 10 days after the ovulatory dose of HCG or GnRHa to support the luteal phase.
Report a problemFND-0988650602
03HumanNon-randomized trialEfficacy outcome
In women undergoing ovarian stimulation, luteal phase length was similar after leuprolide and HCG triggering with common HCG luteal support.
In plain wordsIn women undergoing ovarian stimulation, luteal phase length was similar with leuprolide and HCG triggering.
Peptide
Leuprolide
Outcome
No significant changeLuteal phase length
Study
n = 52
Comparator
HCG 10,000 IU for ovulation induction with the same HCG luteal support
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
0.5 mg single doseAs given in this study (human).
Source sentences
Summary
The mean length of the luteal phase was similar in groups 1 and 2.
3 context sentences(design, population, supporting numbers)
Summary · context
The present report investigated the luteal phase in non-conceptual polyfollicular cycles in 26 patients (group 1) receiving a single dose of 0.5 mg leuprolide acetate to induce ovulation and in a control group of patients (n = 26) (group 2) who were given human chorionic gonadotrophin (HCG) (10,000…
Summary · context
All of them were normal ovulatory women undergoing gonadotrophin ovarian stimulation because of unexplained infertility or male factor.
Summary · context
In both groups of patients two doses of 2500 IU HCG i.m. were given 6 and 10 days after the ovulatory dose of HCG or GnRHa to support the luteal phase.
Report a problemFND-0988650603

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:37 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.